NeuroOne Medical Technologies Files 8-K
Ticker: NMTC · Form: 8-K · Filed: Aug 18, 2025 · CIK: 1500198
| Field | Detail |
|---|---|
| Company | Neuroone Medical Technologies CORP (NMTC) |
| Form Type | 8-K |
| Filed Date | Aug 18, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-update, address-change
TL;DR
NeuroOne Medical just updated its HQ address in an 8-K filing.
AI Summary
On August 18, 2025, NeuroOne Medical Technologies Corporation filed an 8-K report. The filing indicates a change in the company's principal executive offices to 7599 Anagram Dr., Eden Prairie, MN 55344. This is a routine filing related to corporate information.
Why It Matters
This filing updates the company's official address, which is important for regulatory compliance and for investors to have the most current contact information.
Risk Assessment
Risk Level: low — This filing is a routine corporate update and does not contain information that suggests a significant change in the company's risk profile.
Key Players & Entities
- NeuroOne Medical Technologies Corporation (company) — Registrant
- 7599 Anagram Dr., Eden Prairie, MN 55344 (location) — Principal executive offices
- August 18, 2025 (date) — Date of earliest event reported
FAQ
What is the new principal executive office address for NeuroOne Medical Technologies Corporation?
The new principal executive office address is 7599 Anagram Dr., Eden Prairie, MN 55344.
What is the filing date of this 8-K report?
The filing date of this 8-K report is August 18, 2025.
What is the company's state of incorporation?
The company's state of incorporation is Delaware.
What is the IRS Employer Identification Number (EIN) for NeuroOne Medical Technologies Corporation?
The IRS Employer Identification Number is 27-0863354.
What is the company's telephone number?
The company's telephone number is (952) 426-1383.
Filing Stats: 407 words · 2 min read · ~1 pages · Grade level 13 · Accepted 2025-08-18 08:42:19
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share NMTC The Nasdaq Stock Mar
Filing Documents
- ea0253505-8k_neuroone.htm (8-K) — 23KB
- 0001213900-25-077726.txt ( ) — 181KB
- nmtc-20250818.xsd (EX-101.SCH) — 3KB
- nmtc-20250818_lab.xml (EX-101.LAB) — 33KB
- nmtc-20250818_pre.xml (EX-101.PRE) — 22KB
- ea0253505-8k_neuroone_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On August 18, 2025, NeuroOne Medical Technologies Corporation announced that it has received U.S. Food and Drug Administration 510(k) clearance to market its OneRF Trigeminal Nerve Ablation System for use in procedures to create radiofrequency lesions for the treatment of pain, or for lesioning nerve tissue for functional neurosurgical procedures. 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEUROONE MEDICAL TECHNOLOGIES CORPORATION Dated: August 18, 2025 By: /s/ David Rosa David Rosa Chief Executive Officer 2